EMBEDA Drug Patent Profile

When do Embeda patents expire, and what generic alternatives are available?

Embeda is a drug marketed by Alpharma Pharms and is included in one NDA. There are seven patents protecting this drug and four Paragraph IV challenges.

This drug has seventy-four patent family members in twenty-three countries.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this compound. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Embeda

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 19, 2027. This may change due to patent challenges or generic licensing.

There are four Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for EMBEDA

International Patents:	74
US Patents:	7
Applicants:	1
NDAs:	1
Clinical Trials:	7
Drug Prices:	Drug price information for EMBEDA
What excipients (inactive ingredients) are in EMBEDA?	EMBEDA excipients list
DailyMed Link:	EMBEDA at DailyMed

See drug prices for EMBEDA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EMBEDA

Constraining patent/regulatory exclusivity:

8,158,156

NDA:

022321

Dosage:

CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EMBEDA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 1
Pfizer	Phase 4
Pfizer	Phase 3

See all EMBEDA clinical trials

Paragraph IV (Patent) Challenges for EMBEDA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	20 mg/0.8 mg	022321	1	2018-08-16
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	30 mg/1.2 mg 50 mg/2 mg 80 mg/3.2 mg	022321	1	2010-05-28
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	60 mg/2.4 mg	022321	1	2010-05-25
EMBEDA	Extended-release Capsules	morphine sulfate; naltrexone hydrochloride	100 mg/4 mg	022321	1	2010-05-03

US Patents and Regulatory Information for EMBEDA

EMBEDA is protected by seven US patents.

This potential generic entry date is based on patent 8,158,156.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-006	Aug 13, 2009		DISCN	Yes	No	8,846,104		Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009		DISCN	Yes	No	7,815,934		Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-004	Aug 13, 2009		DISCN	Yes	No	7,815,934		Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009		DISCN	Yes	No	8,877,247		Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009		DISCN	Yes	No	7,682,633
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009		DISCN	Yes	No	8,158,156
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-003	Aug 13, 2009		DISCN	Yes	No	7,682,634		Y

Expired US Patents for EMBEDA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009	5,378,474
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-003	Aug 13, 2009	8,685,443
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-004	Aug 13, 2009	8,685,444
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-002	Aug 13, 2009	8,685,444
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009	8,685,443
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009	5,202,128
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-005	Aug 13, 2009	8,685,444

International Patents for EMBEDA

When does loss-of-exclusivity occur for EMBEDA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Austria

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EMBEDA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20150029762	Pharmaceutical compositions
South Korea	20140079441	PHARMACEUTICAL COMPOSITIONS
Denmark	2484346
Slovenia	1551372
Denmark	0609961
Portugal	2526932
Russian Federation	2009101082	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ (PHARMACEUTICAL COMPOSITIONS)

EMBEDA Market Analysis and Financial Projection

Last updated: April 24, 2026

EMBEDA: Market dynamics and financial trajectory

EMBEDA is a branded, extended-release (ER) combination product that contains morphine sulfate (ER) plus naltrexone hydrochloride (immediate-release) in a single capsule. It is positioned to deter misuse through opioid antagonism while delivering sustained opioid exposure.

What is EMBEDA’s market structure and competitive landscape?

EMBEDA sits in the intersection of (1) ER opioid pain therapeutics and (2) abuse-deterrent opioid formulations. The relevant commercial battleground is ER morphine and ER opioid branded franchises where formulary access, payer tiering, and prior authorization policies drive volume.

Core commercial dynamics

• Formulary access is decisive. ER opioids compete on plan coverage, step therapy, and quantity limits, with strong momentum benefits for entrenched brands already on formularies.
• Abuse-deterrent labeling changes formulary behavior but does not eliminate restriction. Payers treat abuse-deterrent products as reduced-risk, yet many still impose PA or require documentation of prior inadequate response or intolerance.
• Hydrocodone ER and other ER opioid classes remain substitutes. Even with abuse-deterrent positioning, clinicians and payers can steer toward competing ER opioids depending on cost and coverage.

Direct market comparables

• ER morphine products (other ER morphine brands and generics)
• ER oxycodone products (brand and generic)
• ER hydromorphone (where covered)
• Abuse-deterrent opioids (class-level substitute category)

Abuse-deterrent framework EMBEDA uses naltrexone as a deterrent approach. When crushed and taken in ways that defeat ER release, naltrexone is designed to antagonize opioid effects, which can reduce “liking” outcomes in misuse settings (mechanism disclosed in product labeling) [1].

---

How has EMBEDA’s financial trajectory evolved (sales, access, and pricing pressures)?

A complete sales-versus-time view requires access to audited IMS/Originator channel data or financial disclosures from the brand owner. This analysis is constrained to publicly stated evidence in sources cited below and product-level market facts, which support the following trajectory pattern:

1. Commercial launch phase (brand establishment)

   • EMBEDA reached the market as an abuse-deterrent ER morphine product intended to expand the ER morphine category by differentiating on misuse deterrence. Its differentiation targets payer and prescriber risk-management priorities (label positioning) [1].

2. Maturation phase (payer management and substitution effects)

   • As generic ER morphine and other ER opioids gained coverage, EMBEDA faced persistent price and formulary pressure typical of opioid brands once generic alternatives expand.
   • In this stage, EMBEDA’s performance typically depends on:
     • whether it stays on preferred tiers,
     • whether it is allowed without step edits,
     • and whether payers treat it as a “preferred abuse-deterrent” option versus a higher-cost alternative.

3. Down-cycle / brand contraction phase

   • When abuse-deterrent opioids face higher co-pays, restrictive prior authorization, or competitor substitution, volumes usually compress even if the product remains covered in some settings. Product-level risk controls like REMS (Risk Evaluation and Mitigation Strategy) also shape channel behavior, though REMS applies across ER opioids with opioids.

REMS and risk-management that affects commercial flow

• Like all opioids with REMS-type controls, EMBEDA operates in a regulated prescribing and dispensing environment that can indirectly affect market uptake and prescriber behavior. EMBEDA’s risk controls and opioid education components are reflected in the opioid product labeling framework [1].

---

What are the key demand drivers for EMBEDA in real-world prescribing?

Clinician selection factors

• Pain management fit: EMBEDA is used for patients who need around-the-clock management and for whom opioid therapy is appropriate.
• Abuse-deterrence criteria: In some payer pathways and certain clinical settings, abuse-deterrent claims influence the likelihood of coverage and continuation.

Payer and pharmacy factors

• Tier placement and prior authorization: Even if covered, EMBEDA can lose volume if placed on non-preferred tiers or subject to step edits.
• Cost sharing and substitutions: High out-of-pocket cost drives switching to lower-cost ER opioids or generics when clinically acceptable.

Regulatory and risk environment

• Opioids face evolving state-level prescribing scrutiny, dosing limits, and pharmacy monitoring programs. Those effects apply broadly and change prescriber behavior across the category [1].

---

Where does EMBEDA fit in the opioid abuse-deterrent portfolio economics?

EMBEDA is one of several abuse-deterrent opioid strategies, competing under a market lens that values:

• evidence of reduced misuse when formulations are tampered with,
• smoother access policies relative to higher-risk alternatives,
• and manufacturer-backed payer support.

The product’s abuse-deterrent strategy depends on naltrexone co-formulation to antagonize opioid effects under certain misuse conditions (as described in labeling) [1]. That mechanism positions it differently from other deterrent technologies (physical barriers, prodrug approaches, etc.), but the payer economic outcome still depends on relative price and coverage.

---

Is EMBEDA’s market trajectory likely to be “brand decline,” “stability,” or “revival”?

Based on the standard commercial pattern for branded ER opioids after generic and competitor coverage expansion:

• Base case trajectory: gradual decline or constrained growth
• Path to stability: preferred formulary placement plus strong evidence of clinical and payer value versus cheaper alternatives
• Low-probability revival: major formulation/patent extension events, successful lifecycle changes, or payer contract outcomes that re-tier the product

This is consistent with how abuse-deterrent ER opioid brands generally behave once broader category substitution is available, with ongoing reliance on payer contracting rather than pure differentiation.

---

What patent and lifecycle factors typically govern EMBEDA’s economics?

EMBEDA’s long-run financial trajectory is heavily shaped by IP and exclusivity. The decisive issues are whether key patents and exclusivities still protect the product from direct AB substitution and whether new entrants or authorized generics compress pricing.

The product’s long-term fate therefore follows:

• patent expiry timeline,
• data exclusivity and other regulatory exclusivity (where applicable),
• and the strength of any formulation or method-of-use protection (if any) against generic entry.

Note: Specific EMBEDA patent expiry dates and current listing status require device-to-patent mapping from Orange Book records and litigation histories, which are not present in the cited sources below. This section is limited to the economic role IP plays in this product class and does not assert specific expiration dates.

---

Key market risk factors impacting EMBEDA performance

1. Generic substitution and price compression across ER morphine options
2. Payer tightening through prior authorization, step therapy, and quantity limits
3. Ongoing opioid risk policy changes that alter prescriber and dispenser behavior
4. Competition from other abuse-deterrent and ER opioid formulations with better contract positioning

Labeling confirms EMBEDA is an opioid ER product with naltrexone deterrence strategy, operating within the standard opioid risk environment [1].

---

Key Takeaways

• EMBEDA is an abuse-deterrent ER morphine plus naltrexone product that competes primarily for formulary and payer access inside the ER opioid market.
• Its market dynamics are dominated by substitution pressure from generics and competing ER opioids, moderated by payer management of abuse-deterrent products.
• Financial trajectory is structurally linked to IP protection and payer contracting; without sustained preferred coverage, branded ER opioids typically face compressed pricing and volume decline.
• The deterrence mechanism using naltrexone is central to payer and clinician decision-making in abuse-deterrent pathways, but it does not prevent category-level substitution dynamics.

---

FAQs

1. What makes EMBEDA different from standard ER morphine?
   EMBEDA combines morphine sulfate ER with naltrexone, intended to antagonize opioid effects if the formulation is manipulated in ways that defeat the ER release pattern [1].

2. Do abuse-deterrent opioids avoid prior authorization?
   No. Many payers still impose coverage controls for opioids; abuse-deterrent labeling can improve approval rates or tiering but does not eliminate payer utilization management [1].

3. What is EMBEDA’s main competitive set?
   ER opioids, especially ER morphine products and other ER opioid franchises that are cheaper or more broadly preferred under payer contracts.

4. What drives EMBEDA sales most strongly?
   Formulary placement, PA/step-edit design, patient cost-sharing, and substitution to lower-cost ER opioid or generic alternatives.

5. What is the biggest financial risk to EMBEDA?
   Erosion of differentiated value through generic entry or competitor re-tiering that reduces payer willingness to cover EMBEDA on preferred terms.

---

References

[1] U.S. Food and Drug Administration. (n.d.). EMBEDA (morphine sulfate and naltrexone hydrochloride) prescribing information / label. FDA. https://www.accessdata.fda.gov/